Pharma Deals Review, Vol 2002, No 29 (2002)

Font Size:  Small  Medium  Large

KS Biomedix Secures European Deal Over TransMID™-R

Business Review Editor

Abstract


KS Biomedix entered into a licensing agreement with Nycomed for its TransMID™-R for the treatment of high grade glioma with a value up to US$60 M. KSB also signed a protein engineering technology licensing agreement with Isis Innovation.

Full Text: pdf

Add comment

Creative Commons License
This work is licensed under a Creative Commons Attribution 3.0 License.